Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing

Damiano Magrì, Federica Re, Giuseppe Limongelli, Piergiuseppe Agostoni, E. Zachara, Michele Correale, Vittoria Mastromarino, Caterina Santolamazza, Martina Casenghi, Giuseppe Pacileo, Fabio Valente, Marco Morosin, B. Musumeci, Erika Pagannone, Antonello Maruotti, Massimo Uguccioni, Massimo Volpe, Camillo Autore

Research output: Contribution to journalArticle

Abstract

Background: Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) in predicting HF-related events. An exercise-derived risk model, the HYPertrophic Exercise-derived Risk HF (HYPERHF), has been developed. Methods and Results: A multicenter cohort of 620 consecutive HCM outpatients was recruited and followed (2007 to 2015). The endpoint was death from HF, cardiac transplantation, NYHA III–IV class progression, severe functional deterioration leading to hospitalization for septal reduction, and hospitalization for HF worsening. During a median follow-up of 3.8 years (25–75th centile: 2.3–5.3 years), 84 patients reached the endpoint. Peak circulatory power (peak oxygen consumption * peak systolic blood pressure), ventilatory efficiency and left atrial diameter were independently associated with the endpoint and, accordingly, integrated into the HYPERHF model (C index: 0.849; best cutoff value equal to 15%). Conclusions: CPET is useful in the evaluation of HCM patients. In this context, the HYPERHF score might allow early identification of those patients at high risk of HF progression and its complications.

Original languageEnglish
Pages (from-to)2204-2211
Number of pages8
JournalCirculation Journal
Volume80
Issue number10
DOIs
Publication statusPublished - 2016

Fingerprint

Hypertrophic Cardiomyopathy
Heart Failure
Exercise
Hospitalization
Blood Pressure
Heart Transplantation
Oxygen Consumption
Outpatients

Keywords

  • Cardiopulmonary exercise test
  • Heart failure
  • Hypertrophic cardiomyopathy
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing. / Magrì, Damiano; Re, Federica; Limongelli, Giuseppe; Agostoni, Piergiuseppe; Zachara, E.; Correale, Michele; Mastromarino, Vittoria; Santolamazza, Caterina; Casenghi, Martina; Pacileo, Giuseppe; Valente, Fabio; Morosin, Marco; Musumeci, B.; Pagannone, Erika; Maruotti, Antonello; Uguccioni, Massimo; Volpe, Massimo; Autore, Camillo.

In: Circulation Journal, Vol. 80, No. 10, 2016, p. 2204-2211.

Research output: Contribution to journalArticle

Magrì, D, Re, F, Limongelli, G, Agostoni, P, Zachara, E, Correale, M, Mastromarino, V, Santolamazza, C, Casenghi, M, Pacileo, G, Valente, F, Morosin, M, Musumeci, B, Pagannone, E, Maruotti, A, Uguccioni, M, Volpe, M & Autore, C 2016, 'Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing', Circulation Journal, vol. 80, no. 10, pp. 2204-2211. https://doi.org/10.1253/circj.CJ-16-0432
Magrì, Damiano ; Re, Federica ; Limongelli, Giuseppe ; Agostoni, Piergiuseppe ; Zachara, E. ; Correale, Michele ; Mastromarino, Vittoria ; Santolamazza, Caterina ; Casenghi, Martina ; Pacileo, Giuseppe ; Valente, Fabio ; Morosin, Marco ; Musumeci, B. ; Pagannone, Erika ; Maruotti, Antonello ; Uguccioni, Massimo ; Volpe, Massimo ; Autore, Camillo. / Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing. In: Circulation Journal. 2016 ; Vol. 80, No. 10. pp. 2204-2211.
@article{3b1fd59a48c340769c8b65684e3065bc,
title = "Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing",
abstract = "Background: Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) in predicting HF-related events. An exercise-derived risk model, the HYPertrophic Exercise-derived Risk HF (HYPERHF), has been developed. Methods and Results: A multicenter cohort of 620 consecutive HCM outpatients was recruited and followed (2007 to 2015). The endpoint was death from HF, cardiac transplantation, NYHA III–IV class progression, severe functional deterioration leading to hospitalization for septal reduction, and hospitalization for HF worsening. During a median follow-up of 3.8 years (25–75th centile: 2.3–5.3 years), 84 patients reached the endpoint. Peak circulatory power (peak oxygen consumption * peak systolic blood pressure), ventilatory efficiency and left atrial diameter were independently associated with the endpoint and, accordingly, integrated into the HYPERHF model (C index: 0.849; best cutoff value equal to 15{\%}). Conclusions: CPET is useful in the evaluation of HCM patients. In this context, the HYPERHF score might allow early identification of those patients at high risk of HF progression and its complications.",
keywords = "Cardiopulmonary exercise test, Heart failure, Hypertrophic cardiomyopathy, Prognosis",
author = "Damiano Magr{\`i} and Federica Re and Giuseppe Limongelli and Piergiuseppe Agostoni and E. Zachara and Michele Correale and Vittoria Mastromarino and Caterina Santolamazza and Martina Casenghi and Giuseppe Pacileo and Fabio Valente and Marco Morosin and B. Musumeci and Erika Pagannone and Antonello Maruotti and Massimo Uguccioni and Massimo Volpe and Camillo Autore",
year = "2016",
doi = "10.1253/circj.CJ-16-0432",
language = "English",
volume = "80",
pages = "2204--2211",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

TY - JOUR

T1 - Heart failure progression in hypertrophic cardiomyopathy - Possible insights from cardiopulmonary exercise testing

AU - Magrì, Damiano

AU - Re, Federica

AU - Limongelli, Giuseppe

AU - Agostoni, Piergiuseppe

AU - Zachara, E.

AU - Correale, Michele

AU - Mastromarino, Vittoria

AU - Santolamazza, Caterina

AU - Casenghi, Martina

AU - Pacileo, Giuseppe

AU - Valente, Fabio

AU - Morosin, Marco

AU - Musumeci, B.

AU - Pagannone, Erika

AU - Maruotti, Antonello

AU - Uguccioni, Massimo

AU - Volpe, Massimo

AU - Autore, Camillo

PY - 2016

Y1 - 2016

N2 - Background: Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) in predicting HF-related events. An exercise-derived risk model, the HYPertrophic Exercise-derived Risk HF (HYPERHF), has been developed. Methods and Results: A multicenter cohort of 620 consecutive HCM outpatients was recruited and followed (2007 to 2015). The endpoint was death from HF, cardiac transplantation, NYHA III–IV class progression, severe functional deterioration leading to hospitalization for septal reduction, and hospitalization for HF worsening. During a median follow-up of 3.8 years (25–75th centile: 2.3–5.3 years), 84 patients reached the endpoint. Peak circulatory power (peak oxygen consumption * peak systolic blood pressure), ventilatory efficiency and left atrial diameter were independently associated with the endpoint and, accordingly, integrated into the HYPERHF model (C index: 0.849; best cutoff value equal to 15%). Conclusions: CPET is useful in the evaluation of HCM patients. In this context, the HYPERHF score might allow early identification of those patients at high risk of HF progression and its complications.

AB - Background: Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) in predicting HF-related events. An exercise-derived risk model, the HYPertrophic Exercise-derived Risk HF (HYPERHF), has been developed. Methods and Results: A multicenter cohort of 620 consecutive HCM outpatients was recruited and followed (2007 to 2015). The endpoint was death from HF, cardiac transplantation, NYHA III–IV class progression, severe functional deterioration leading to hospitalization for septal reduction, and hospitalization for HF worsening. During a median follow-up of 3.8 years (25–75th centile: 2.3–5.3 years), 84 patients reached the endpoint. Peak circulatory power (peak oxygen consumption * peak systolic blood pressure), ventilatory efficiency and left atrial diameter were independently associated with the endpoint and, accordingly, integrated into the HYPERHF model (C index: 0.849; best cutoff value equal to 15%). Conclusions: CPET is useful in the evaluation of HCM patients. In this context, the HYPERHF score might allow early identification of those patients at high risk of HF progression and its complications.

KW - Cardiopulmonary exercise test

KW - Heart failure

KW - Hypertrophic cardiomyopathy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84988628698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988628698&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-16-0432

DO - 10.1253/circj.CJ-16-0432

M3 - Article

VL - 80

SP - 2204

EP - 2211

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -